Jupiter Neurosciences wins exclusive U.S. rights to ALA-002

Jupiter Neurosciences signed a definitive license agreement with PharmAla Biotech Holdings for perpetual exclusive U.S. rights to ALA-002, a patented MDMA-based drug candidate with FDA Novel Chemical Entity designation. The deal could be worth up to $100 million and pushes Jupiter into a second clinical-stage CNS program alongside its Parkinson’s disease asset.

Why it matters: - The agreement gives Jupiter Neurosciences a second clinical-stage CNS asset and broadens the company beyond a single-program strategy. - ALA-002 carries FDA Novel Chemical Entity designation, which can provide stronger regulatory protection and five years of data exclusivity after approval. - The deal could create a U.S. commercialization path for Jupiter if ALA-002 advances successfully. - The transaction also deepens Jupiter’s exposure to the psychedelic therapeutics market, where management sees long-term growth potential.

What happened: - Jupiter Neurosciences signed a definitive license agreement with PharmAla Biotech Holdings for perpetual exclusive U.S. rights to ALA-002. - The company disclosed the deal on July 22, 2026. - Jupiter said the transaction could reach up to $100 million, including milestone payments, excluding ongoing royalties. - The agreement covers a patented, non-racemic MDMA formulation. - Jupiter said the transaction expands the company from a single-program developer into a dual clinical-stage CNS company.

The details: - Jupiter will pay $3.3 million upfront, split between $1.5 million in cash and $1.8 million in Jupiter common stock, with a 120-day lock-up. - A $3.3 million development milestone is due upon Phase 3 first patient in. - A $20 million regulatory milestone is due upon U.S. NDA approval. - Commercial milestones are set at $10 million, $30 million and $33.3 million when cumulative U.S. net sales reach $333 million, $1 billion and $2 billion. - Jupiter will owe a 3% royalty on net sales after the third commercialization milestone. - PharmAla will continue to manufacture ALA-002 drug product for Jupiter under commercial terms still to be negotiated. - The company said this manufacturing arrangement should accelerate development timelines. - ALA-002 has been engineered to improve cardiovascular safety and reduce abuse liability versus racemic MDMA while preserving the therapeutic effects tied to MDMA-assisted psychotherapy. - PharmAla’s MDMA supply is already active in U.S. government-sponsored VA and DHA clinical trials. - Jupiter said the addressable U.S. psychedelic therapeutics market was estimated at $3 billion in 2024 and is projected to reach $8 billion by 2030, citing Strategic Market Research. - Jupiter said the agreement aligns with the April 18, 2026 executive order titled "Accelerating Medical Treatments for Serious Mental Illness," which directed the FDA and DEA to expand access to investigational psychedelic therapies. - The order includes a Right to Try pathway, Commissioner's National Priority Vouchers for 1-2 month expedited FDA reviews for Breakthrough Therapy-designated psychedelic drugs, and $50 million in ARPA-H funding for psychedelic medicine programs. - Jupiter’s current lead program, JOTROL, is a proprietary enhanced-bioavailability resveratrol formulation in a Phase IIa Parkinson’s disease trial. - Jupiter also commercializes Nugevia, a consumer longevity supplement.

Between the lines: - The deal gives Jupiter a second asset with a potentially faster regulatory profile than many early-stage CNS programs because of the NCE designation and the policy backdrop around psychedelic medicines. - Jupiter is pairing a traditional neurodegenerative disease program with a psychedelic therapeutics asset, which could diversify both clinical risk and market opportunity. - The stock component in the upfront payment signals that Jupiter is preserving cash while still giving PharmAla equity exposure. - Management framed the agreement as part of a broader CNS and brain-plasticity strategy, but the company still faces the usual clinical, regulatory and financing risks tied to drug development.

What's next: - Jupiter said the next focus is clinical execution, capital allocation and advancing both programs toward development milestones. - PharmAla will keep advancing ALA-002 outside the United States while Jupiter handles the U.S. rights. - The agreement still depends on the usual clinical, regulatory and financing steps before any approval or commercialization. - Jupiter also said the new board expertise it has added supports execution in psychedelic medicines over the next 12 months.

The bottom line: - Jupiter has turned itself into a two-asset CNS developer with an exclusive U.S. psychedelic drug right that could become a meaningful value driver if the program clears clinical and regulatory hurdles.